Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Trial Details

NCT ID

NCT06442475

Phase

PHASE2

Sponsor

University of Washington

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Mosunetuzumab
Positron Emission Tomography
Questionnaire Administration

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

18 years or older at time of signing informed consent
Capable of understanding and providing written informed consent
Histologically confirmed indolent B-cell non-Hodgkin lymphoma with no prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are all…
Follicular lymphoma (grade 1-2 or 3A)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →